Influence of the route of immunization and the nature of the bacterial vector on immunogenicity of mucosal vaccines based on lactic acid bacteria

Vaccine

Volumn 25, Issue 36, 2007, Pages 6581-6588

  Cortes Perez, Naima G ^a   Lefèvre, François ^b   Corthier, Gérard ^a   Adel Patient, Karine ^c   Langella, Philippe ^a   Bermúdez Humarán, Luis G ^a  

^a CEMAGREF   (France)

^b INRA Institut National de la Recherche Agronomique   (France)

^c Bâtiment 136 CEA de Saclay   (France)

Author keywords

E7; HPV 16; Immunotherapy; Lactic acid bacteria; Lactobacillus plantarum; Lactococcus lactis; Mucosal vaccines

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 12; PROTEIN E7;

ADOLESCENT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BACTERIAL STRAIN; CANCER REGRESSION; CONTROLLED STUDY; CYTOKINE RELEASE; FEMALE; GENETIC ENGINEERING; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNIZATION; IMMUNOGENICITY; IMMUNOMODULATION; LACTIC ACID BACTERIUM; LACTOBACILLUS PLANTARUM; LACTOCOCCUS LACTIS; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL;

EID: 34547812592     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.06.062     Document Type: Article

References (42)

1. Ruedl C., Rieser C., Kofler N., Wick G., and Wolf H. Humoral and cellular immune responses in the murine respiratory tract following oral immunization with cholera toxin or Escherichia coli heat-labile enterotoxin. Vaccine 14 (1996) 792-798
2. Hvalbye B.K., Aaberge I.S., Lovik M., and Haneberg B. Intranasal immunization with heat-inactivated Streptococcus pneumoniae protects mice against systemic pneumococcal infection. Infect Immun 67 (1999) 4320-4325
3. Cong H., Gu Q.M., Jiang Y., He S.Y., Zhou H.Y., Yang T.T., et al. Oral immunization with a live recombinant attenuated Salmonella typhimurium protects mice against Toxoplasma gondii. Parasite Immunol 27 (2005) 29-35
4. Belyakov I.M., Isakov D., Zhu Q., Dzutsev A., and Berzofsky J.A. A novel functional CTL avidity/activity compartmentalization to the site of mucosal immunization contributes to protection of macaques against simian/human immunodeficiency viral depletion of mucosal CD4+ T cells. J Immunol 178 (2007) 7211-7221
5. Hanniffy S., Wiedermann U., Repa A., Mercenier A., Daniel C., Fioramonti J., et al. Potential and opportunities for use of recombinant lactic acid bacteria in human health. Adv Appl Microbiol 56 (2004) 1-64
6. Bermúdez-Humarán L.G., Corthier G., and Langella P. Recent advances in the use of Lactococcus lactis as live recombinant vector for the development of new safe mucosal vaccines. Recent Res Dev Microbiol 8 (2004) 147-160
7. Dennehy M., and Williamson A.L. Factors influencing the immune response to foreign antigen expressed in recombinant BCG vaccines. Vaccine 23 (2005) 1209-1224
8. Atkins H.S., Morton M., Griffin K.F., Stokes M.G., Nataro J.P., and Titball R.W. Recombinant Salmonella vaccines for biodefence. Vaccine 24 (2006) 2710-2717
9. Phalipon A., and Sansonetti P. Live attenuated Shigella flexneri mutants as vaccine candidates against Shigellosis and vectors for antigen delivery. Biologicals 23 (1995) 125-134
10. Adams M.R., and Marteau P. On the safety of lactic acid bacteria from food. Int J Food Microbiol 27 (1995) 263-264
11. Kelly D., Conway S., and Aminov R. Commensal gut bacteria: mechanisms of immune modulation. Trends Immunol 26 (2005) 326-333
12. Cortes-Perez N.G., Bermúdez-Humarán L.G., Le Loir Y., Rodriguez-Padilla C., Gruss A., et al. Mice immunization with live lactococci displaying a surface anchored HPV-16 E7 oncoprotein. FEMS Microbiol Lett 229 (2003) 37-42
13. Bermúdez-Humarán L.G., Cortes-Perez N.G., Le Loir Y., Alcocer-Gonzalez J.M., Tamez-Guerra R.S., de Oca-Luna R.M., et al. An inducible surface presentation system improves cellular immunity against human papillomavirus type 16 E7 antigen in mice after nasal administration with recombinant lactococci. J Med Microbiol 53 (2004) 427-433
14. Bermúdez-Humarán L.G., Langella P., Cortes-Perez N.G., Gruss A., Taméz-Guerra R.S., Oliveira S.C., et al. Intranasal immunization with recombinant Lactococcus lactis secreting murine interleukin-12 enhances antigen-specific Th1 cytokine production. Infect Immun 71 (2003) 1887-1896
15. Bermúdez-Humarán L.G., Cortes-Perez N.G., Lefevre F., Guimaraes V., Rabot S., Alcocer-Gonzalez J.M., et al. A novel mucosal vaccine based on live lactococci expressing E7 antigen and IL-12 induces systemic and mucosal immune responses and protects mice against human papillomavirus type 16-induced tumors. J Immunol 175 (2005) 7297-7302
16. Cortes-Perez N.G., Azevedo V., Alcocer-Gonzalez J.M., Rodriguez-Padilla C., Tamez-Guerra R.S., et al. Cell-surface display of E7 antigen from human papillomavirus type-16 in Lactococcus lactis and in Lactobacillus plantarum using a new cell-wall anchor from lactobacilli. J Drug Target 3 (2005) 89-98
17. Lin K.Y., Guarnieri F.G., Staveley-O'Carroll K.F., Levitsky H.I., August J.T., Pardoll D.M., et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 56 (1996) 21-26
18. Bermúdez-Humarán L.G., Langella P., Miyoshi A., Gruss A., Guerra R.T., et al. Production of human papillomavirus type 16 E7 protein in Lactococcus lactis. Appl Environ Microbiol 68 (2002) 917-922
19. Adel-Patient K., Nahori M.A., Proust B., Lapa e Silva J.R., Creminon C., Wal J.M., et al. Elicitation of the allergic reaction in beta-lactoglobulin-sensitized Balb/c mice: biochemical and clinical manifestations differ according to the structure of the allergen used for challenge. Clin Exp Allergy 33 (2003) 376-385
20. Cortes-Perez N.G., Ah-Leung S., Bermúdez-Humarán L.G., Corthier G., Wal J.M., Langella P., et al. Intranasal coadministration of live lactococci producing interleukin-12 and a major cow's milk allergen inhibits allergic reaction in mice. Clin Vaccine Immunol 14 (2007) 226-233
21. Krchnak V., Vagner J., Suchankova A., Krcmar M., Ritterova L., and Vonka V. Synthetic peptides derived from E7 region of human papillomavirus type 16 used as antigens in ELISA. J Gen Virol 71 (1990) 2719-2724
22. Feltkamp M.C., Smits H.L., Vierboom M.P., Minnaar R.P., de Jongh B.M., et al. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol 23 (1993) 2242-2249
23. Tindle R.W., Fernando G.J., Sterling J.C., and Frazer I.H. A public T-helper epitope of the E7 transforming protein of human papillomavirus 16 provides cognate help for several E7 B-cell epitopes from cervical cancer-associated human papillomavirus genotypes. Proc Natl Acad Sci USA 88 (1991) 5887-5891
24. Angiolillo A.L., Sgadari C., Taub D.D., Liao F., Farber J.M., et al. Human interferon-inducible protein 10 is a potent inducer of angiogenesis in vivo. J Exp Med 182 (1995) 155-162
25. Brunda M.J., Luistro L., Hendrzack J.A., Fountolakis M., Garotta G., and Gateley M.K. Role of IFN- + in mediating the antitumor efficacy of IL-12. J Immunother 17 (1995) 71-77
26. Strasly M., Cavallo F., Geuna M., Mitola S., Colombo M.P., Forni G., et al. IL-12 inhibition of endothelial cell functions and angiogenesis depends on lymphocyte-endothelial cell cross-talk. J Immunol 166 (2001) 3890-3899
27. Valosky J., Hishiki H., Zaoutis T.E., and Coffin S.E. Induction of mucosal B-cell memory by intranasal immunization of mice with respiratory syncytial virus. Clin Diagn Lab Immunol 12 (2005) 171-179
28. Oliveira M.L., Areas A.P., Campos I.B., Monedero V., Perez-Martinez G., et al. Induction of systemic and mucosal immune response and decrease in Streptococcus pneumoniae colonization by nasal inoculation of mice with recombinant lactic acid bacteria expressing pneumococcal surface antigen A. Microbes Infect 8 (2006) 1016-1024
29. Cheun H.I., Kawamoto K., Hiramatsu M., Tamaoki H., Shirahata T., Igimi S., et al. Protective immunity of SpaA-antigen producing Lactococcus lactis against Erysipelothrix rhusiopathiae infection. J Appl Microbiol 96 (2004) 1347-1353
30. Ramasamy R., Yasawardena S., Zomer A., Venema G., Kok J., and Leenhouts K. Immunogenicity of a malaria parasite antigen displayed by Lactococcus lactis in oral immunisations. Vaccine 24 (2006) 3900-3908
31. Robinson K., Chamberlain L.M., Schofield K.M., Wells J.M., and Le Page R.W. Oral vaccination of mice against tetanus with recombinant Lactococcus lactis. Nat Biotechnol 15 (1997) 653-657
32. Foligne B., Nutten S., Grangette C., Dennin V., Goudercourt D., Poiret S., et al. Correlation between in vitro and in vivo immunomodulatory properties of lactic acid bacteria. World J Gastroenterol 13 (2007) 236-243
33. Pavan S., Desreumaux P., and Mercenier A. Use of mouse models to evaluate the persistence, safety, and immune modulation capacities of lactic acid bacteria. Clin Diagn Lab Immunol 10 (2003) 696-701
34. Daniel C., Repa A., Wild C., Pollak A., Pot B., Breiteneder H., et al. Modulation of allergic immune responses by mucosal application of recombinant lactic acid bacteria producing the major birch pollen allergen Bet v 1. Allergy 61 (2006) 812-819
35. Grangette C., Nutten S., Palumbo E., Morath S., Hermann C., Dewulf J., et al. Enhanced antiinflammatory capacity of a Lactobacillus plantarum mutant synthesizing modified teichoic acids. Proc Natl Acad Sci USA 102 (2005) 10321-10326
36. Vesa T., Pochart P., and Marteau P. Pharmacokinetics of Lactobacillus plantarum NCIMB, 8826 Lactobacillus fermentum KLD, and Lactococcus lactis MG1363 in the human gastrointestinal tract. Aliment Pharmacol Ther 14 (2000) 823-828
37. Klijn N., Weerkamp A.H., and de Vos W.M. Genetic marking of Lactococcus lactis shows its survival in the human gastrointestinal tract. Appl Environ Microbiol 61 (1995) 2771-2774
38. Drouault S., Corthier G., Ehrlich S.D., and Renault P. Survival, physiology, and lysis of Lactococcus lactis in the digestive tract. Appl Environ Microbiol 65 11 (1999) 4881-4886
39. Wells J.M., Robinson K., Chamberlain L.M., Schofield K.M., and Le Page R.W. Lactic acid bacteria as vaccine delivery vehicles. Antonie Leeuwenhoek 70 (1996) 317-330
40. Robinson K., Chamberlain L.M., Lopez M.C., Rush C.M., Marcotte H., Le Page R.W., et al. Mucosal and cellular immune responses elicited by recombinant Lactococcus lactis strains expressing tetanus toxin fragment C. Infect Immun 72 (2004) 2753-2761
41. Grangette C., Muller-Alouf H., Goudercourt D., Geoffroy M.C., Turneer M., and Mercenier A. Mucosal immune responses and protection against tetanus toxin after intranasal immunization with recombinant Lactobacillus plantarum. Infect Immun 69 (2001) 1547-1553
42. Corthesy B., Boris S., Isler P., Grangette C., and Mercenier A. Oral immunization of mice with lactic acid bacteria producing Helicobacter pylori urease B subunit partially protects against challenge with Helicobacter felis. J Infect Dis 192 (2005) 1441-1449